Masahiro Ogasawara

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

Jun Imagawa, Hideo Tanaka, Masaya Okada et al. · The Lancet Haematology · 2015 · 300 citations

Medicine, Hematology, Oncology +4

The Membrane-type Collectin CL-P1 Is a Scavenger Receptor on Vascular Endothelial Cells

Katsuki Ohtani, Yasuhiko Suzuki, Souji Eda et al. · Journal of Biological Chemistry · 2001 · 214 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment

Masaya Okada, Jun Imagawa, Hideo Tanaka et al. · Clinical Lymphoma Myeloma & Leukemia · 2018 · 117 citations · Full text

Medicine, Oncology, Pharmacology +9

Green light emitting diodes accelerate wound healing: Characterization of the effect and its molecular basis in vitro and in vivo

Tomohiro Fushimi, Shigeki Inui, Takeshi Nakajima et al. · Wound Repair and Regeneration · 2012 · 109 citations

Natural Sciences, Dermatology, Molecular Biology +17

The role of the UL41 gene of herpes simplex virus type 1 in evasion of non-specific host defence mechanisms during primary infection

Tatsuo Suzutani, Masayoshi Nagamine, Taiichiro Shibaki et al. · Microbiology · 2000 · 93 citations

Life Sciences, Infectious Diseases, Molecular Biology +15